Emeka Patrick Chukwuka: The Numbers Don’t Lie, But Context Matters
Emeka Patrick Chukwuka, Hematologist and Clinical Pathologist, shared a post on LinkedIn:
“Clinical Haematology Education Series – Teaching Case 03
A 42-year-old male with confirmed homozygous sickle cell disease (Hb SS) attended routine haematology review. Serial HPLC over 10 months told a story that almost changed his diagnosis — until the transfusion record was checked.
The finding: Hb A, which should be absent in true Hb SS, reappeared — jumping from 0% to 24.3%, then falling back to 9.1% over approximately nine weeks.
The question every haematologist must ask: Is this a co-inherited β⁺-thalassaemia allele making this Hb S/β⁺-thal — or is this transfused donor blood clearing from circulation?
The answer lies in the trajectory.
- A genotypic Hb A fraction (as in Hb S/β⁺-thal) is proportionally stable visit to visit — it doesn’t spike and decay.
- A transfusion-derived Hb A follows the donor red cell lifespan (~120 days) — a sharp rise, then a gradual fall as donor cells senesce. Here, the 0% to 24.3% and then to 9.1% curve fits transfusion kinetics precisely. The timing correlated with a red cell transfusion 2–8 weeks prior.
The teaching pearl: In confirmed Hb SS, Hb A on HPLC or electrophoresis is transfusion-derived until the blood bank record proves otherwise — never a standalone basis for reclassifying genotype.
Practical implications are significant: Do not reclassify Hb SS as a compound heterozygote on electrophoresis alone.
Defer %HbS/%HbF targets for hydroxyurea or exchange transfusion until more than 3 months post-transfusion.
Always correlate HPLC with transfusion history before signing out the report
This case is a reminder that laboratory context is clinical context. The numbers don’t lie — but they do require the right question.”
Stay updated with Hemostasis Today.
-
Sep 8, 2026, 16:14Heghine Khachatryan: Colombo 2026 Insights on Point-of-Care Ultrasound in Hemophilia Joint Care
-
Sep 8, 2026, 15:57Flora Peyvandi: Efficiency Meets Innovation in Hemophilia B Gene Therapy
-
Sep 8, 2026, 15:48Maxime Dely: Guillain-Barré Syndrome – What if the Key Lies in the Plasma?
-
Sep 8, 2026, 15:34Ron DePinho: A Negative Trial Highlights the Need for Precision in Cardiovascular Inflammation
-
Sep 8, 2026, 15:31Adil Yousaf: Thrombolysis Speed Matters, but Eligibility Comes First
-
Sep 8, 2026, 15:28Dhargam Aljebouri: First Molecularly Characterized Para-Bombay Phenotype in the Arab World
-
Sep 8, 2026, 15:27Mohd Ashhad: How Much Does Hemoglobin Increase After 1 Unit of PRBC?
-
Sep 8, 2026, 15:27Sanish Babu: The Hematocrit–Platelet Signal in Severe Dengue
-
Sep 8, 2026, 15:26Mary Kama: Climate-Informed Early Warning Systems for Sickle Cell Anaemia